化学
药品
癌症治疗
抗体
癌症
抗体-药物偶联物
结合
药理学
单克隆抗体
免疫学
内科学
医学
数学分析
数学
作者
Meiyang Xi,Jingjing Zhu,Fengxia Zhang,Hualiang Shen,Jianhui Chen,Zixuan Xiao,Yanping Huangfu,Chunlei Wu,Haopeng Sun,Gang Xia
标识
DOI:10.1016/j.ejmech.2024.116709
摘要
Antibody-drug conjugates (ADCs) represent a promising cancer therapy modality which specifically delivers highly toxic payloads to cancer cells through antigen-specific monoclonal antibodies (mAbs). To date, 15 ADCs have been approved and more than 100 ADC candidates have advanced to clinical trials for the treatment of various cancers. Among these ADCs, microtubule-targeting and DNA-damaging agents are at the forefront of payload development. However, several challenges including toxicity and drug resistance limit the potential of this modality. To tackle these issues, multiple innovative payloads such as immunomodulators and proteolysis targeting chimeras (PROTACs) are incorporated into ADCs to enable multimodal cancer therapy. In this review, we describe the mechanism of ADCs, highlight the importance of ADC payloads and summarize recent progresses of conventional and unconventional ADC payloads, trying to provide an insight into payload diversification as a key step in future ADC development.
科研通智能强力驱动
Strongly Powered by AbleSci AI